one
main
advantag
use
lentivector
capac
transduc
wide
rang
cell
type
independ
cell
cycl
stage
howev
transgen
express
certain
cell
type
sometim
desir
either
toxic
cell
transform
induct
transgenespecif
immun
respons
case
specif
target
cancer
cell
within
tumor
sought
deliveri
suicid
gene
consequ
great
effort
invest
develop
strategi
control
transgen
deliveryexpress
celltissuespecif
manner
strategi
broadli
divid
three
particl
pseudotyp
surfac
target
entail
modif
envelop
glycoprotein
env
transcript
target
util
cellspecif
promot
andor
induc
promot
posttranscript
target
recent
appli
lentivector
introduc
sequenc
target
cellspecif
microrna
chapter
describ
strategi
provid
illustr
exampl
lentivector
effect
transduc
wide
rang
cell
properti
allow
gene
correct
potenti
cell
type
hand
circumst
transgen
express
desir
limit
number
specif
cell
target
exampl
intraven
lentivector
administr
result
gene
transfer
hepatocyt
mous
model
howev
also
lead
transgen
express
profession
antigen
present
cell
plasmacytoid
dendrit
cell
pdc
cell
trigger
transgenespecif
immun
respons
result
elimin
transgeneexpress
hepatocyt
collater
transduct
limit
therapeut
efficaci
gene
therapi
protocol
therefor
case
dc
transduct
avoid
cost
circumst
transgen
express
immun
cell
therapeut
exampl
express
particular
mitogen
activ
protein
kinas
mapk
constitut
activ
myeloid
dc
either
enhanc
antitumor
immun
respons
inhibit
immun
respons
modul
dc
function
hand
mapk
modul
may
favor
cell
transform
express
poorli
differenti
cell
type
therefor
restrict
transgen
deliveri
immun
cell
would
increas
biosafeti
final
transgen
may
toxic
particular
cell
lineag
certain
differenti
stage
exemplifi
correct
gene
therapi
globoid
cell
leukodystrophi
lysosom
storag
diseas
caus
inactiv
mutat
galactocerebrosidas
galc
galc
express
highli
toxic
earli
hematopoiet
progenitor
therapeut
matur
cell
hematopoiet
lineag
interest
case
specif
transgen
deliveri
achiev
accord
cellular
differenti
stage
henc
mani
circumst
specif
target
cell
type
tissu
achiev
therefor
lentivector
tropism
modul
mani
experiment
approach
focu
bestknown
exampl
transgen
deliveri
lentivector
depend
recognit
target
cell
env
follow
entri
cell
therefor
lentivector
tropism
first
determin
specif
bind
cell
surfac
receptor
discuss
chap
lentivector
acquir
wide
rang
differ
envelop
glycoprotein
bud
plasma
membran
produc
cell
process
call
pseudotyp
result
virion
pseudovirion
exhibit
surfac
antigen
provid
heterolog
env
env
use
pseudotyp
lentivector
although
lead
high
titer
prepar
reason
one
wide
use
envelop
lentivector
pseudotyp
vesicular
stomat
viru
glycoprotein
vsvg
vsvg
pseudotyp
exhibit
mani
advantag
firstli
stabil
vector
particl
lead
high
titer
vector
prepar
allow
vector
concentr
ultracentrifug
due
stabil
secondli
vsvg
pantrop
envelop
confer
broad
host
cell
rang
fact
unclear
whether
vsvg
bind
specif
ubiquit
cell
receptor
bind
phospholipid
plasma
membran
howev
case
restrict
lentivector
tropism
result
safer
vivo
gene
deliveri
also
enhanc
therapeut
effect
reduc
lentivector
dose
interest
sinc
reach
high
titer
retroviru
vector
prepar
major
difficulti
reason
sever
strategi
appli
achiev
specif
transduct
target
surfac
modif
env
explain
avail
broad
rang
exist
viral
env
combin
capac
retroviruslentiviru
vector
accommod
heterolog
env
make
strategi
simpl
straightforward
lentivector
exhibit
celltissu
tropism
viru
env
origin
galv
env
use
correct
xlink
chronic
granulomat
diseas
cgd
wiskottaldrich
syndrom
contrast
correct
xlink
adrenoleukodystrophi
bthalassaemia
achiev
vsvg
pseudotyp
lentivector
superior
transduct
effici
lentivector
also
effect
pseudotyp
envelop
protein
distant
viru
famili
tabl
includ
alphaviru
envelop
ross
river
viru
semliki
forest
viru
exhibit
specif
tropism
toward
mous
human
dendrit
cell
baculoviru
insect
viru
envelop
confer
high
particl
stabil
transduct
effici
lentivector
pseudotyp
effect
transduc
hepatocyt
vivo
cell
hematopoiet
lineag
poorli
includ
dc
properti
exploit
prevent
transgenespecif
immun
respons
lymphocyt
choriomening
lcmv
viru
env
pseudotyp
transduc
cell
central
nervou
system
neuron
neuroblast
astrocyt
glioma
cell
also
insulin
secret
b
cell
list
lentivector
pseudotyp
applic
long
howev
one
case
worth
explain
detail
due
relev
b
cell
human
gene
therapi
gene
modif
nonactiv
b
lymphocyt
alway
scientif
challeng
effici
transduct
requir
activ
usual
agonist
antibodi
pretreat
cytokin
activ
alter
phenotyp
effector
function
transduc
even
vsvg
lentivector
pseudotyp
transduc
nonactiv
cell
ineffici
interestingli
effici
transduct
nonactiv
human
lymphocyt
achiev
measl
viru
h
f
env
hf
pseudotyp
measl
viru
hf
bind
slam
lead
effici
viru
entri
nuclear
transport
integr
lentivector
also
transduc
b
cell
lymphoma
particularli
resist
lentivector
transduct
exampl
especi
last
one
demonstr
possibl
find
adequ
env
pseudotyp
target
cell
type
bind
function
tropism
env
pseudotyp
also
alter
modif
env
residu
involv
receptor
bind
case
origin
tropism
complet
abrog
without
affect
fusion
activ
molecul
antibodi
cytokin
receptor
ligand
provid
altern
bind
method
exampl
alter
natur
tropism
env
achiev
specif
dc
tropism
introduct
select
mutat
sindbi
viru
envelop
protein
bind
heparan
sulfat
present
cell
type
also
dcsign
dcspecif
molecul
bind
cell
receptor
mediat
membran
fusion
interestingli
fusion
activ
independ
bind
cell
receptor
specif
mutat
abolish
bind
heparan
sulfat
dcsign
modif
allow
specif
lentivector
gene
transfer
dc
vivo
sindbi
envelop
system
also
suscept
target
strategi
case
bind
capac
complet
abrog
provid
altern
bind
method
alongsid
pseudotyp
exampl
cellspecif
antibodi
conjug
confer
specif
tropism
toward
pglycoproteinexpress
melanoma
cell
prostat
cancer
endotheli
cell
hematopoiet
progenitor
cell
strong
antibodi
conjug
achiev
introduc
zz
domain
protein
incorpor
antibodi
surfac
molecul
alongsid
modifi
sindbi
env
effect
target
lentivector
specif
cell
type
major
setback
sindbisbas
modif
strategi
depend
endocytosi
phdepend
fusion
occur
physic
retarget
lentivector
guarante
endocytosi
fortun
pseudotyp
measl
viru
fh
envelop
glycoprotein
circumv
hurdl
h
subunit
mediat
cell
bind
f
protein
trigger
phindepend
fusion
therefor
fh
lentivector
pseudotyp
gain
access
direct
fusion
plasma
membran
similarli
sindbi
viru
system
measl
viru
h
subunit
bind
residu
mutat
bound
differ
molecul
target
specif
ligand
exampl
fusion
either
epiderm
growth
factor
egf
singlechain
antibodi
result
specif
lentivector
transduct
egf
receptor
express
cell
b
lymphocyt
respect
note
author
studi
remark
high
b
cell
transduct
effici
howev
possibl
measl
viru
hf
envelop
system
main
determin
b
cell
modif
engin
retarget
envelop
protein
coval
fusion
natur
ligand
cytokin
prove
challeng
strategi
limit
success
inclus
ligand
usual
inhibit
viral
entri
limit
except
sindbi
measl
viru
envelop
system
one
exampl
fusion
influenza
heamaglutinin
egf
target
retrovir
transduct
egf
receptorexpress
cell
overcom
inhibit
vector
entri
sequenc
target
cellular
proteas
metalloproteas
mmp
introduc
releas
env
fuse
ligand
antibodi
strategi
also
appli
target
mmpexpress
tumor
use
retroviru
lentiviru
vector
select
target
transgen
express
specif
cell
type
effect
achiev
cell
tissuespecif
promot
situat
lentivector
transduct
prevent
cell
entri
rather
transgen
express
restrict
specif
cell
type
larg
number
endogen
cellular
promot
potenti
allow
target
express
cell
type
tissu
addit
induc
promot
also
incorpor
lentivector
system
lead
control
transgen
express
administr
given
drug
strategi
add
addit
control
point
develop
cellspecif
lentivector
specif
cell
type
express
achiev
incorpor
promot
activ
specif
cell
lentivector
endogen
cellular
promot
addit
less
sensit
promot
silenc
key
human
gene
therapi
silenc
cretrovir
promot
loss
transgen
express
could
contribut
patient
death
cgd
clinic
trial
use
endogen
cellular
promot
result
improv
stabil
longev
transgen
express
target
cell
consequ
wide
rang
endogen
promot
introduc
retroviru
lentiviru
transfer
vector
use
approach
sometim
combin
viral
enhanc
endogen
promot
specif
gene
express
achiev
number
cell
type
tissu
erythroid
cell
endotheli
cell
retin
cell
neuron
glial
cell
sever
cell
type
hippocampu
cell
liver
also
target
intraven
lentivector
administr
use
specif
promot
effect
restrict
express
hepatocyt
particular
case
benefit
cellspecif
gene
express
clearli
shown
use
albumin
promot
result
longterm
transgen
express
rat
liver
contrast
transgen
express
cytomegaloviru
promot
cmv
rapidli
silenc
importantli
hepatocytespecif
promot
prevent
transgen
express
profession
antigen
present
cell
could
rais
transgenespecif
immun
respons
exemplifi
correct
mucopolysaccharidosi
type
mous
model
lentivector
gene
therapi
diseas
caus
aliduronidas
idua
defici
lead
toxic
glycosaminoglycan
accumul
wide
rang
cell
correct
reli
express
idua
liver
intraven
administr
therapeut
lentivector
howev
idua
also
express
antigen
present
cell
limit
efficaci
durabl
correct
prevent
idua
express
control
albumin
promot
result
longterm
express
liver
minim
transgenespecif
immun
respons
cancer
cell
also
specif
target
use
tumour
cellspecif
promot
lentivector
contain
metalloproteasespecif
promot
use
express
proapoptot
gene
bax
tbid
cancer
cell
line
afetoprotein
promot
use
deliv
suicid
gene
hepatocarcinoma
cell
prostat
specif
antigen
psa
promot
target
prostat
cancer
cell
fact
lentivector
deliv
diphtheria
toxin
gene
control
psa
promot
use
erad
prostat
cancer
cell
cultur
mous
tumor
model
experiment
set
transgen
express
requir
immun
cell
particularli
dc
dc
compris
group
special
profession
antigen
present
cell
regul
control
immun
respons
dcspecif
express
achiev
induc
antitumor
immun
use
hla
dra
promot
hand
transcript
target
dc
appli
achiev
immun
suppress
exampl
transgenespecif
toler
achiev
lentivectormedi
promotercontrol
express
transgen
mice
specif
dc
target
achiev
immunolog
toler
widen
applic
gene
therapi
approach
treatment
autoimmun
diseas
prevent
graftversushost
diseas
mention
possibl
one
complex
tissuesorgan
target
central
nervou
system
exhibit
high
cellular
divers
instanc
transcript
target
prove
reliabl
techniqu
mani
cellular
promot
effect
express
neuron
glial
hippocampu
cell
synapsin
promot
enolas
promot
promot
glial
fibrillari
acid
protein
vimentin
promot
case
high
longlast
transgen
express
achiev
promot
less
effici
fact
often
case
endogen
promot
strong
viral
origin
boost
endogen
promot
retain
cell
specif
research
modifi
particular
cellspecif
promot
combin
promot
ad
enhanc
artifici
transcript
activ
case
bidirect
promot
minim
cmv
promot
posit
next
cellspecif
promot
lead
transcript
opposit
direct
way
transgen
express
target
cell
enhanc
combin
sever
promot
within
construct
also
allow
cellspecif
express
one
transgen
exampl
interphotoreceptor
retinoid
bind
protein
promot
guanyl
cyclas
activ
protein
promot
evalu
togeth
rhodopsin
promot
combin
aim
achiev
specif
express
two
trangen
retin
cell
specif
case
promot
design
critic
achiev
therapeut
activ
human
gene
therapi
patient
suffer
bthalassaemia
contain
nonfunct
allel
bglobin
result
mark
reduct
express
patient
reli
lifelong
blood
transfus
obviou
approach
correct
diseas
drive
bglobin
express
erythroid
cell
although
straightforward
theoret
point
view
accomplish
relev
function
bglobin
express
challeng
achiev
care
engin
lentivir
vector
includ
bglobin
gene
transcript
control
endogen
promot
intron
locu
control
region
fig
summar
long
list
cellspecif
promot
success
appli
lentivir
vector
sure
improv
perform
safeti
gene
therapi
transgen
express
also
control
use
regulat
promot
capac
regul
transgen
express
crucial
treatment
genet
diseas
time
level
express
critic
typic
exampl
addit
immedi
flank
region
endogen
bglobin
gene
includ
indic
arrow
addit
chicken
hypersensit
site
bglobin
insul
sequenc
place
within
ltr
prevent
silenc
express
cassett
transcript
transactiv
adjac
host
gene
pleas
note
lentivector
selfinactiv
construct
chap
minilocu
place
within
lentivector
construct
revers
orient
diabet
high
blood
glucos
level
trigger
insulin
secret
mani
research
group
develop
induc
promot
mani
system
incorpor
lentivector
probabl
one
first
wide
use
system
util
tetracyclin
induct
briefli
two
main
variat
tetracyclin
system
teton
lead
induc
transgen
express
tetracyclin
doxycyclin
deliveri
tetoff
need
constant
antibiot
administr
prevent
transgen
express
obviou
reason
teton
system
prefer
gene
therapi
publish
lentivector
system
belong
categori
except
case
tetracyclineinduc
system
also
prone
inactiv
leaki
transcript
vivo
applic
straightforward
overcom
disadvantag
tetracyclinedepend
induc
system
system
also
adapt
lentivector
drosophila
ecdyson
receptor
system
base
bind
either
ecdyson
synthet
analog
heterodimer
protein
made
herpex
simplex
viru
protein
activ
domain
fuse
ecdyson
receptor
vgecr
retinoid
x
receptor
rxr
vgecrrxr
bind
induc
promot
drive
gene
transcript
howev
system
depend
administr
multipl
lentivector
backbon
recent
success
reduc
singl
lentivector
backbon
fuse
tetracyclin
repressor
kruppelassoci
box
krab
domain
repressor
novel
fusion
protein
act
regul
system
achiev
tightli
regul
condit
transgen
express
brain
druginduc
transgen
mous
model
gene
silenc
hematopoiet
cell
quit
number
induc
system
also
adapt
lentivector
system
glucocorticoid
induc
promot
mifepristoneinduc
system
also
mani
promot
upregul
depend
activ
state
differ
cell
type
case
promot
util
report
construct
exampl
nfjb
transactivat
promot
engin
fuse
nfjb
bind
site
upstream
minim
cmv
promot
drive
express
report
fluoresc
protein
addit
tolllik
receptor
tlr
agonist
lp
dc
modifi
lentivector
result
strong
transcript
upregul
fluoresc
protein
interferon
b
promot
also
achiev
similar
result
promot
could
use
express
transgen
follow
dc
activ
although
appli
therapeut
set
yet
without
doubt
discoveri
regulatori
system
gene
express
base
small
noncod
rna
microrna
mirna
revolution
biomed
research
small
noncod
nt
rna
term
sirna
partial
complementari
wide
rang
mrna
posttranscript
inhibit
gene
express
either
lead
mrna
degrad
translat
repress
mrna
destabil
mirna
activ
regul
complex
mechan
mani
variat
depend
speci
therefor
briefli
oversimplifi
describ
main
step
control
mirna
regul
anim
cell
firstli
activ
sirna
encod
within
larg
precursor
rna
molecul
call
mirna
fig
transcrib
rna
polymeras
ii
long
precursor
mirna
recogn
special
enzymat
pathway
pasha
drosha
releas
sirna
form
short
hairpin
shrna
sirna
refer
hairpin
stem
togeth
complementari
strand
particular
case
complementari
strand
also
play
regulatori
role
shrna
activ
export
nucleu
cytoplasm
recogn
enzym
complex
dicer
dcr
degrad
shrna
leav
stem
contain
sirna
target
complementari
sequenc
mirnamirna
duplex
duplex
load
ago
complex
argonaut
form
prerisc
rna
interfer
silenc
complex
subsequ
mirna
strand
degrad
leav
complementari
mirna
intact
within
risc
complex
risc
complex
scan
mrna
suffici
complement
found
target
mrna
mirna
strand
mrna
degrad
case
polya
tail
remov
lead
mrna
destabil
altern
mrna
translat
may
stall
fig
mechan
exploit
cell
specif
target
transgen
express
fact
strikingli
simpl
differ
cell
type
express
differ
pattern
mirna
intim
involv
regul
cell
differenti
therefor
transgen
deliv
lentivector
contain
target
complementari
endogen
express
mirna
cell
type
cell
type
b
transgen
express
take
place
cell
type
b
transgen
mrna
degrad
type
alon
fig
system
call
mirna
tag
howev
satur
system
high
mrna
level
satur
risc
complex
mrna
excess
translat
although
result
reduc
express
level
mirna
tag
technolog
quickli
appli
solv
major
problem
lentivector
gene
therapi
direct
vivo
lentivector
administr
lead
rather
effici
transgenespecif
immun
respons
desir
characterist
boost
immun
detriment
gene
therapi
geneticmetabol
disord
transgenespecif
immun
respons
dramat
limit
therapeut
activ
surviv
correct
cell
solv
problem
transgen
express
abrog
cell
hematopoiet
lineag
includ
four
copi
sequenc
target
hematopoieticspecif
mirna
downstream
transgen
code
sequenc
strategi
ensur
mrna
encod
transgen
would
degrad
cell
hematopoiet
lineag
lymphocyt
granulocyt
importantli
macrophag
dc
consequ
intraven
administr
lentivector
result
lack
transgenespecif
immun
respons
sustain
longterm
transgen
express
hepatocyt
interestingli
strategi
result
transgenespecif
toler
shown
expans
regulatori
cell
treg
curious
detarget
antigen
fig
simplifi
mechan
microrna
mir
pathway
simpl
scheme
product
function
mirnadepend
control
gene
express
shown
cell
nucleu
upper
part
mirna
encod
larg
cap
rna
molecul
transcrib
cellular
rna
polymeras
ii
larg
precursor
recogn
protein
complex
contain
drosha
pasha
remov
sirna
segment
short
rna
hairpin
present
specif
stemloop
secondari
structur
shrna
export
cytoplasm
bound
dicer
degrad
shrna
leav
mirnamirna
duplex
mirna
refer
complementari
sequenc
actual
target
sequenc
duplex
load
protein
complex
contain
argonaut
prerna
interfer
silenc
complex
prerisc
mirna
strand
duplex
degrad
risc
contain
complementari
strand
target
sequenc
use
scan
mrna
molecul
exhibit
total
partial
complementar
match
occur
mrna
either
degrad
destabil
translat
repress
express
apc
result
treg
expans
experiment
set
antigen
present
play
critic
role
differenti
expans
antigenspecif
treg
interestingli
author
demonstr
use
mirnadetarget
strategi
transgen
express
hepatocyt
requir
immunolog
toler
detarget
transgen
express
use
mirna
effect
allow
factor
ix
express
liver
without
rais
immun
respons
lead
correct
hemophilia
b
mous
model
anoth
applic
mirna
tag
transgen
express
correspond
specif
differenti
activ
stage
util
target
mirna
lentivector
contain
four
copi
target
sequenc
ideal
mirna
target
lr
shown
red
caption
transcript
mrna
produc
encod
gene
interest
follow
mirna
target
sequenc
mrna
transport
nucleu
cellular
cytoplasm
lower
panel
cell
express
mirna
left
panel
rna
silenc
complex
risc
contain
mirna
blue
comb
bind
complementari
target
sequenc
present
mrna
red
comb
recognit
lead
disrupt
gene
translat
particular
mrna
either
degrad
shown
inhibit
translat
cell
express
mirna
gene
express
occur
normal
translat
right
panel
differenti
stagedepend
variabl
express
level
exampl
transgen
express
achiev
immatur
dc
combin
differ
mirna
target
achiev
transgen
express
specif
cell
type
within
given
tissu
anoth
exampl
target
express
cell
differ
differenti
stage
introduct
mirna
target
sequenc
particular
mirna
express
endotheli
epitheli
cell
addit
hematopoiet
stem
cell
express
pattern
exploit
target
express
galc
matur
cell
hematopoiet
lineag
correct
globoid
cell
leukodystrophi
curious
galc
express
hematopoiet
stem
cell
earli
progenitor
highli
toxic
contrast
therapeut
matur
cell
hematopoiet
lineag
therefor
correct
diseas
four
copi
mirna
target
sequenc
place
downstream
galc
gene
consequ
galc
express
matur
hematopoiet
cell
lead
diseas
correct
final
mirna
tag
also
exploit
track
differenti
pathway
util
express
pattern
report
gene
contain
distinct
mirna
target
sequenc
three
main
group
lentivector
target
strategi
promis
therapeut
applic
surfac
target
ensur
specif
entri
therapeut
vector
target
cell
use
specif
promot
restrict
transgen
express
transduct
nontarget
cell
occur
final
mirna
tag
add
anoth
level
control
transgen
express
fact
three
strategi
alreadi
appli
treatment
hemophilia
baculoviru
lentivector
drive
express
factor
viii
albumin
promot
combin
mirna
tag
avoid
transgen
express
apc
appli
mous
model
hemophilia
strikingli
particular
case
suffici
prevent
factor
viiispecif
immun
respons
even
though
liverspecif
express
achiev
macrophag
deplet
lentivector
administr
perform
achiev
therapeut
fviii
level
result
experi
difficult
explain
mirna
tag
alon
suffici
correct
hemophilia
b
without
induc
fixspecif
immun
respons
last
case
demonstr
even
though
combin
sever
target
strategi
avoid
transgenespecif
immun
respons
look
promis
specif
target
viral
vector
cell
tissu
still
challeng
